The relationship between serum homocysteine and post-stroke epolepsy_Journal of Epilepsy

Authors：

ZHOU Xiaomin ,  ZHANG Zhongsheng

Department of Neurology, Qingyuan Hospital affiliated to Guangzhou Medical University, Qingyuan 511500, China;

Corresponding?author：

ZHANG Zhongsheng, Email: zzsllokyy@sohu.com

Keywords：

Epilepsy; Homocysteine; Poststroke seizures; Antiseizure medications; Comorbidity

DOI：

10.7507/2096-0247.202402001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Homocysteine is an intermediate product of methionine and cysteine metabolism, and plays a key role in methylation. Epilepsy is one of the common diseases of the nervous system, long-term repeated seizures will not only cause damage to the brain tissue, but also cause cognitive impairment. At present, the clinical treatment for epilepsy is still mainly to control symptoms, the fundamental etiology of epilepsy still needs to be improved, to explore the etiology of seizures, fundamentally control seizures, is still our long-term struggle direction. High homocysteine is associated with many diseases. Epidemiological studies have shown that the serum homocysteine level of 10% ~ 40% of epilepsy patients is higher than that of the normal population. By exploring the relationship between serum Hcy and epilepsy,We expect to provide help for the diagnosis and treatment of clinical epilepsy.

Citation： ZHOU Xiaomin, ZHANG Zhongsheng. The relationship between serum homocysteine and post-stroke epolepsy. Journal of Epilepsy, 2024, 10(3): 260-264. doi: 10.7507/2096-0247.202402001 Copy

1.	Beghi E, D'Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology, 2011, 77(20): 1785-1793.
2.	肖波, 周羅. 癲癇最新臨床診療指南: 機遇與挑戰并存. 協和醫學雜志, 2017, 8(Z1): 122-126.
3.	李世綽. 述評: 國際抗癲癇事業最新進展(概述). 中風與神經疾病雜志, 2023, 40(6): 483-487.
4.	Yang B, Fan S, Zhi X, et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients, 2014, 7(1): 74-90.
5.	Zeng Y, Li FF, Yuan SQ, et al. Prevalence of hyperhomocysteinemia in China: an updated meta-analysis. Biology (Basel), 2021, 10(10): 12560.
6.	閆晗, 向瑞, 楊吉春, 等. 同型半胱氨酸代謝與疾病. 生理科學進展, 2023, 54(4): 290-296.
7.	孔娟. 高同型半胱氨酸血癥診療專家共識. 腫瘤代謝與營養電子雜志, 2020, 7(3): 283-288.
8.	Gurda D, Handschuh L, Kotkowiak W, et al. Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids, 2015, 47(7): 1319-1339.
9.	王學峰. 癲癇研究新進展. 中國現代神經疾病雜志, 2022, 22(7): 543-548.
10.	梁錦平. 國際抗癲癇聯盟2017年版癲癇分類特點及其解讀. 中國實用兒科雜志, 2020, 35(1): 47-54.
11.	沈新月, 石鄭浩, 侯一瑋, 等. 同型半胱氨酸與癲癇關系的研究進展. 濱州醫學院學報, 2020, 43(2): 149-151.
12.	Swanger SA, Chen W, Wells G, et al. Mechanistic Insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains. Am J Hum Genet, 2016, 99(6): 1261-1280.
13.	Jakubowski H. Homocysteine Modification in protein structure/function and human disease. Physiol Rev, 2019, 99(1): 555-604.
14.	Hansen J, ?sberg S, Kumlien E, et al. Cause of death in patients with poststroke epilepsy: results from a nationwide cohort study. PLoS One, 2017, 12(4): e0174659.
15.	Merkler AE, Gialdini G, Lerario MP, et al. Population-based assessment of the long-term risk of seizures in survivors of stroke. Stroke, 2018, 49(6): 1319-1324.
16.	Xu MY. Poststroke seizure: optimising its management. Stroke Vasc Neurol, 2019, 4(1): 48-56.
17.	Johan Zelano, Martin Holtkamp, Nivedita Agarwal, et al. How to diagnose and treat post-stroke seizures and epilepsy. Epileptic Disord, 2020, 22(3): 252-263.
18.	侯宇婷, 石佳琦, 王洋, 等. 腦卒中后癇性發作與腦卒中后癲癇的研究進展. 中華神經醫學雜志, 2018, 17(11): 1185-1188.
19.	Zhang T, Jiang Y, Zhang S, et al. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine (Baltimore), 2020, 99(12): e19467.
20.	王艾, 譚博, 張愛玲, 等. 同型半胱氨酸對腦梗死患者血管內皮細胞功能的影響. 檢驗醫學與臨床, 2015, 12(01): 121-123.
21.	陳杰瑩, 黃江佼, 陽海金, 等. 高同型半胱氨酸與深靜脈血栓形成的相關研究. 醫學綜述, 2010, 16(20): 3096-3098.
22.	Kumar A, Palfrey H A, Pathak R, et al. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond), 2017, 14(78.
23.	王浩, 聶談, 朱楊. 腦卒中后癲癇發作的臨床特點、腦電圖表現及危險因素分析. 江西醫藥, 2019, 54(07): 769-771+813.
24.	劉盛佳, 郭馬, 王周. 腦卒中患者血清Hcy及NSE水平與癲癇發作的相關性研究. 現代檢驗醫學雜志, 2022, 37(1): 177-181.
25.	李承霞, 湛長青, 龐洪波. 148例腦卒中后癲癇發作患者的臨床分析. 癲癇與神經電生理學雜志, 2019, 28(5): 288-292,296.
26.	史穎, 金鑫, 張新欣, 等. 補充葉酸、維生素B12治療腦卒中后癲癇合并高同型半胱氨酸血癥的臨床療效. 中西醫結合心腦血管病雜志, 2021, 19(22): 3994-3997.
27.	Jakubus T, Michalska-Jakubus M, Lukawski K, et al. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep, 2009, 61(3): 411-423.
28.	鄒蓉, 戴永萍, 趙合慶. 抗癲癇藥物對卒中后癲癇患者血清同型半胱氨酸、葉酸、B族維生素水平的影響. 臨床神經病學雜志, 2017, 30(2): 93-97.
29.	Mahmoud AA, Aboelghar HM, Abdelmageed SM, et al. Assessment of asymmetric dimethylarginine and homocysteine in epileptic children receiving antiepileptic drugs. Pediatr Res, 2022, 92(6): 1606-1612.
30.	Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci, 2005, 98(4): 340-353.
31.	Tümer L, Serdaro?lu A, Hasano?lu A, et al. Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Paediatr, 2002, 91(9): 923-926.
32.	郭亞培, 劉恒方, 張敏, 等. 血清同型半胱氨酸和血漿C反應蛋白、D-二聚體在癲癇患者中的表達水平及與服藥種類的關系. 實用醫學雜志, 2019, 35(5): 747-750.
33.	徐珊珊, 王小姍, 余傳勇, 等. 不同抗癲癇藥物對卒中后癲癇患者血Hcy影響及葉酸、維生素B_(12)的干預效果. 腦與神經疾病雜志, 2023, 31(5): 311-315.
34.	Emeksiz HC, Serdaroglu A, Biberoglu G, et al. Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure, 2013, 22(2): 124-127.
35.	Rasic-Markovic A, Hrncic D, Krstic D, et al. The effect of subchronic supplementation with folic acid and l-arginine on homocysteine-induced seizures. Can J Physiol Pharmacol, 2016, 94(10): 1083-1089.
36.	居春陽, 王琳晶, 朱雨嵐. 高同型半胱氨酸血癥在癲癇患者中的研究進展. 中華神經醫學雜志, 2012, 11(4): 428-430.
37.	Ono H, Sakamoto A, Mizoguchi N, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev, 2002, 24(4): 223-226.
38.	鄒蓉, 趙合慶, 徐興順. 伴有同型半胱氨酸增高的老年癲癇患者維生素B補充治療的臨床價值. 中華神經科雜志, 2017, 50(4): 250-254.
39.	Chen K, Yang LN, Lai C, et al. Role of Grina/Nmdara1 in the central nervous system diseases. Curr Neuropharmacol, 2020, 18(9): 861-867.
40.	李嬌健, 董巖, 郎朗, 等. 血清同型半胱氨酸與癲癇患者認知功能損害的關系探討. 河北醫學, 2017, 23(1): 35-37.
41.	Sampson EL, Blanchard MR, Jones L, et al. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry, 2009, 195(1): 61-66.
42.	張爽. 血清同型半胱氨酸與癲癇患者認知功能損害的關系研究. 中國醫學創新, 2019, 16(1): 152-155.
43.	Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2003, 2(8): 473-481.
44.	邱小娥. 血漿同型半胱氨酸水平、腦萎縮與認知障礙的相關性研究. 實用預防醫學, 2011, 18(4): 618-620.
45.	黃苑. 奧卡西平和丙戊酸鈉對癲癇患者血漿同型半胱氨酸和不對稱二甲基精氨酸水平的影響. 中國實用神經疾病雜志, 2016, 19(13): 70-71.

1. Beghi E, D'Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology, 2011, 77(20): 1785-1793.
2. 肖波, 周羅. 癲癇最新臨床診療指南: 機遇與挑戰并存. 協和醫學雜志, 2017, 8(Z1): 122-126.
3. 李世綽. 述評: 國際抗癲癇事業最新進展(概述). 中風與神經疾病雜志, 2023, 40(6): 483-487.
4. Yang B, Fan S, Zhi X, et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients, 2014, 7(1): 74-90.
5. Zeng Y, Li FF, Yuan SQ, et al. Prevalence of hyperhomocysteinemia in China: an updated meta-analysis. Biology (Basel), 2021, 10(10): 12560.
6. 閆晗, 向瑞, 楊吉春, 等. 同型半胱氨酸代謝與疾病. 生理科學進展, 2023, 54(4): 290-296.
7. 孔娟. 高同型半胱氨酸血癥診療專家共識. 腫瘤代謝與營養電子雜志, 2020, 7(3): 283-288.
8. Gurda D, Handschuh L, Kotkowiak W, et al. Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids, 2015, 47(7): 1319-1339.
9. 王學峰. 癲癇研究新進展. 中國現代神經疾病雜志, 2022, 22(7): 543-548.
10. 梁錦平. 國際抗癲癇聯盟2017年版癲癇分類特點及其解讀. 中國實用兒科雜志, 2020, 35(1): 47-54.
11. 沈新月, 石鄭浩, 侯一瑋, 等. 同型半胱氨酸與癲癇關系的研究進展. 濱州醫學院學報, 2020, 43(2): 149-151.
12. Swanger SA, Chen W, Wells G, et al. Mechanistic Insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains. Am J Hum Genet, 2016, 99(6): 1261-1280.
13. Jakubowski H. Homocysteine Modification in protein structure/function and human disease. Physiol Rev, 2019, 99(1): 555-604.
14. Hansen J, ?sberg S, Kumlien E, et al. Cause of death in patients with poststroke epilepsy: results from a nationwide cohort study. PLoS One, 2017, 12(4): e0174659.
15. Merkler AE, Gialdini G, Lerario MP, et al. Population-based assessment of the long-term risk of seizures in survivors of stroke. Stroke, 2018, 49(6): 1319-1324.
16. Xu MY. Poststroke seizure: optimising its management. Stroke Vasc Neurol, 2019, 4(1): 48-56.
17. Johan Zelano, Martin Holtkamp, Nivedita Agarwal, et al. How to diagnose and treat post-stroke seizures and epilepsy. Epileptic Disord, 2020, 22(3): 252-263.
18. 侯宇婷, 石佳琦, 王洋, 等. 腦卒中后癇性發作與腦卒中后癲癇的研究進展. 中華神經醫學雜志, 2018, 17(11): 1185-1188.
19. Zhang T, Jiang Y, Zhang S, et al. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine (Baltimore), 2020, 99(12): e19467.
20. 王艾, 譚博, 張愛玲, 等. 同型半胱氨酸對腦梗死患者血管內皮細胞功能的影響. 檢驗醫學與臨床, 2015, 12(01): 121-123.
21. 陳杰瑩, 黃江佼, 陽海金, 等. 高同型半胱氨酸與深靜脈血栓形成的相關研究. 醫學綜述, 2010, 16(20): 3096-3098.
22. Kumar A, Palfrey H A, Pathak R, et al. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond), 2017, 14(78.
23. 王浩, 聶談, 朱楊. 腦卒中后癲癇發作的臨床特點、腦電圖表現及危險因素分析. 江西醫藥, 2019, 54(07): 769-771+813.
24. 劉盛佳, 郭馬, 王周. 腦卒中患者血清Hcy及NSE水平與癲癇發作的相關性研究. 現代檢驗醫學雜志, 2022, 37(1): 177-181.
25. 李承霞, 湛長青, 龐洪波. 148例腦卒中后癲癇發作患者的臨床分析. 癲癇與神經電生理學雜志, 2019, 28(5): 288-292,296.
26. 史穎, 金鑫, 張新欣, 等. 補充葉酸、維生素B12治療腦卒中后癲癇合并高同型半胱氨酸血癥的臨床療效. 中西醫結合心腦血管病雜志, 2021, 19(22): 3994-3997.
27. Jakubus T, Michalska-Jakubus M, Lukawski K, et al. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep, 2009, 61(3): 411-423.
28. 鄒蓉, 戴永萍, 趙合慶. 抗癲癇藥物對卒中后癲癇患者血清同型半胱氨酸、葉酸、B族維生素水平的影響. 臨床神經病學雜志, 2017, 30(2): 93-97.
29. Mahmoud AA, Aboelghar HM, Abdelmageed SM, et al. Assessment of asymmetric dimethylarginine and homocysteine in epileptic children receiving antiepileptic drugs. Pediatr Res, 2022, 92(6): 1606-1612.
30. Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci, 2005, 98(4): 340-353.
31. Tümer L, Serdaro?lu A, Hasano?lu A, et al. Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Paediatr, 2002, 91(9): 923-926.
32. 郭亞培, 劉恒方, 張敏, 等. 血清同型半胱氨酸和血漿C反應蛋白、D-二聚體在癲癇患者中的表達水平及與服藥種類的關系. 實用醫學雜志, 2019, 35(5): 747-750.
33. 徐珊珊, 王小姍, 余傳勇, 等. 不同抗癲癇藥物對卒中后癲癇患者血Hcy影響及葉酸、維生素B_(12)的干預效果. 腦與神經疾病雜志, 2023, 31(5): 311-315.
34. Emeksiz HC, Serdaroglu A, Biberoglu G, et al. Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure, 2013, 22(2): 124-127.
35. Rasic-Markovic A, Hrncic D, Krstic D, et al. The effect of subchronic supplementation with folic acid and l-arginine on homocysteine-induced seizures. Can J Physiol Pharmacol, 2016, 94(10): 1083-1089.
36. 居春陽, 王琳晶, 朱雨嵐. 高同型半胱氨酸血癥在癲癇患者中的研究進展. 中華神經醫學雜志, 2012, 11(4): 428-430.
37. Ono H, Sakamoto A, Mizoguchi N, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev, 2002, 24(4): 223-226.
38. 鄒蓉, 趙合慶, 徐興順. 伴有同型半胱氨酸增高的老年癲癇患者維生素B補充治療的臨床價值. 中華神經科雜志, 2017, 50(4): 250-254.
39. Chen K, Yang LN, Lai C, et al. Role of Grina/Nmdara1 in the central nervous system diseases. Curr Neuropharmacol, 2020, 18(9): 861-867.
40. 李嬌健, 董巖, 郎朗, 等. 血清同型半胱氨酸與癲癇患者認知功能損害的關系探討. 河北醫學, 2017, 23(1): 35-37.
41. Sampson EL, Blanchard MR, Jones L, et al. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry, 2009, 195(1): 61-66.
42. 張爽. 血清同型半胱氨酸與癲癇患者認知功能損害的關系研究. 中國醫學創新, 2019, 16(1): 152-155.
43. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2003, 2(8): 473-481.
44. 邱小娥. 血漿同型半胱氨酸水平、腦萎縮與認知障礙的相關性研究. 實用預防醫學, 2011, 18(4): 618-620.
45. 黃苑. 奧卡西平和丙戊酸鈉對癲癇患者血漿同型半胱氨酸和不對稱二甲基精氨酸水平的影響. 中國實用神經疾病雜志, 2016, 19(13): 70-71.

Journal of Epilepsy

The relationship between serum homocysteine and post-stroke epolepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content